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Abstract 
 
The Indian pharmaceutical industry is presently going through a phase of transition and 
potential consolidation, owing to India’s new TRIPS-compliant intellectual property 
regime and other rules aimed at enhancing the industry’s credibility nationally and 
internationally. Appropriate policy interventions can play a large role in cushioning the 
transition (and gradual consolidation) of the industry post-2005. Using firm level data 
collected in 2004-2005, this paper seeks to make two major contributions in this regard. 
The research findings show that the Indian pharmaceutical sector is a heterogeneous mix 
of firms with vast differences in innovative capabilities. Based on these differences, the 
groups can be categorized into specific “innovation modes” (the innovator, the niche 
operator and the manufacturer), each mode being a step closer towards the innovative 
pharmaceutical firm. Second, the paper highlights how the emerging strategies of firms 
in all three groups, although different, underpin the importance of systemic 
coordination in the pharmaceutical sector. The analysis links both these findings to 
                                                 
1 Padmashree Gehl Sampath works as researcher at the United Nations University- Institute for 
New Technologies, Keizer Karelplein 19, 6211 TC Maastricht, The Netherlands, tel. 0031-43-
3506300. This paper is based on a study that was conducted by the author for the Commission on 
Intellectual Property Rights, Innovation and Health (CIPIH) of the World Health Organisation, 
titled: Economic Aspects of Access to Medicines Post-2005: Product Patent Protection and 
Emerging Firm Strategies in the Indian Industry, available at: 
http://www.who.int/intellectualproperty/studies/PadmashreeSampathFinal.pdf 
The author is grateful to Prof. Banji Oyeyinka for his helpful comments on an earlier draft of this 
paper. Research assistance by Vladimir Raymond and Bertha Vallejo is acknowledged. 
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policies pursued in the pharmaceutical sector over the past four decades and highlights 
the role of differential innovation policy in ensuring optimal sectoral performance.  
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1. Introduction 
 
Innovation is the process of acquiring technological knowledge and building further 
upon it, from a variety of market and non-market institutions. Technological knowledge 
for innovative activities can either be codified (in the form of publications, patents, blue 
prints), or tacit (embedded in know-how, informal habits and practices of 
organizations). It can also be  scientific knowledge such as basic principles of a 
technological discipline; or technological knowledge in the form of “technical solutions”; 
or even entrepreneurial knowledge related to product attributes, consumer tastes and 
market conditions (Karlsson and Johansson, 2004; Johansson and Lööf, 2006). 
 
Traditional approaches to study how the structure of firms affects innovation trends and 
innovation outputs centred on a firm’s R&D efforts: using a firm’s R&D intensity with 
R&D expenditure as inputs and patent filings as outputs, or explaining a firm’s R&D 
intensity using a firm’s size and market characteristics as explanatory variables. More 
recently, four different approaches seem to be significant (see Johansson and Lööf, 2006). 
Scholars looking at firms from a dynamic capabilities building perspective view firms in 
terms of their aggregate human and material resources, and analyze the efficient 
building of technological capabilities within the administrative organization of the firm 
(Penrose, 1959; Pisano and Teece, 1995, Teece et al, 1997, among others). Other studies 
look at how the characteristics of firms and markets affect a firm’s ability to innovate 
from the perspective of corporate structure, specifically, by creating a distinction 
between local and multinational firms (see Pavitt and Patel, 1999; Narula, 2003, among 
others). There are others who seek to explain innovation activities of firms by looking at 
the functional characteristics of the region in which they locate (clustering), and the basis 
for such agglomeration (see Saxenian, 1994; Porter, 1998). A fourth approach stresses on 
the characteristics of the innovation system in which the innovative activities of a firm 
are entrenched and how this determines capabilities (see Lundvall, 1992; Nelson, 1993). 
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1.1. Firms and ‘catching-up’: the relevance of institutional arrangements 
 
Firms play a central role in driving the innovation process by combining knowledge 
from both internal and external sources, but they do not act alone (OECD, 1999; 2002). 
Firms tend to pass through “cycles” of learning and maturation, driving the innovation 
process ahead with them. Broadly, firms transit through four main stages in their search 
for innovative capabilities: the static firm, the self-generating firm and the innovative 
firm (Little, 2001).2 At one end of the spectrum is the static firm; one which is not 
involved in systematic innovation, but may have a stable market position so long as 
status quo continues. The surviving firm is one that has the ability to adapt to newer 
environments, can question existing rules and routines. It is able to learn new learning 
processes, and reinvent itself to compete in newer environments. The self-generating 
firm is one step further; it not only has the ability to question rules and routines and 
learn new processes to adapt to new environments, but also has the capacity to 
strategically re-position its activities and thrive. At the other end of the spectrum is the 
innovative firm, which is a firm operating a linked set of processes that are involved 
either in concept generation or market identification, product and process development, 
and subsequent production, marketing and feedback of the products (Little 2001). 
Although firms are constantly involved in learning at each one of these stages, the kind 
of learning and associated innovative intensity differs. 
 
Information and knowledge are the primary inputs to the process of building innovative 
capacity in firms, but they originate from within the firm and outside (from the system). 
All infrastructural elements, human-capital and physical, for assessing demand for 
products, manufacturing, marketing, forging customer relationships, accumulating 
information related to production, form part of the system. The particular system of 
innovation within which a firm operates is the basic institutional arrangement that 
determines how its links with other organizations both research-based and market-
                                                 
2 Innovation scholars have struggled for quite sometime now to classify firms similarly. One of the early 
attempts of this kind was made by Freeman and Soete (1997). This classification here is adapted from Little 
(2001). Little (2001) identifies four forms of firm stages: the static firm, the learning firm, the self-
generating firm and the innovative firm. The term ‘learning’ firm has been changed to the ‘surviving’ firm 
here. 
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oriented, such as universities, public research institutes, suppliers, manufacturers, 
consumers and producers occurs and how collaborative and competitive relationships 
will be built upon. Institutions, such as universities (for human capital provision), 
financial institutions (for venture capital and financing of research), industrial 
infrastructure (for manufacturing products or acquiring information related to 
production), entrepreneurial associations (for marketing and assessment of market-
based conditions), all provide incentives (or disincentives) for interaction, thereby 
facilitating or limiting a firm’s ability to tap all knowledge sources, both internal and 
external. Therefore, learning efficiency of firms depends on numerous country-specific 
institutional, infrastructural and cultural elements that pre-determine interactive 
capabilities, organizational efficiencies and mobility of skills (see for example, OECD, 
1999). Secondly, knowledge accumulation can occur in firms only if there is competence 
locally that can be used to build innovative capabilities in the first place. And finally, 
innovation is not an activity that can merely be measured by how much is spent on 
R&D, but rather by how much of research inputs get translated into 
research/commercially viable outputs by the creative use of technological knowledge 
(Amsden and Cho, 2003). All these factors stress on the extensive and complementary 
relationship between firms and the system of innovation in which they are embedded 
for building innovative capabilities. Systemic efficiency is critical in explaining the 
success of firms in reaching the innovative stage: not only do firms which do not have 
these facilities fail, but firms which have these facilities but lack innovative capabilities 
sometimes manage to succeed, and often do so, at the cost of innovative firms that lack 
them (Chesbrough and Teece, 1996).3  
 
Different countries offer very different basis for firm-level innovation activities, most of 
which can be attributed to country size and general level of development (OECD, 2002). 
Institutional arrangements required to promote a particular innovation system are 
influenced largely by the context-specific nature of the process (level of technology and 
the quality of scientific and technological infrastructure) as well as the nature of 
                                                 
3  Teece (1986) and Chesbrough and Teece (1996) note the same although applying a different 
approach to study the process of building innovative capability. In Teece’s words, a firm’s 
capability to innovate is influenced by the “appropriability regime” in which it operates.  
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institutions within the country (the scientific culture, norms and practices of actors and 
support systems) (Oyeyinka and Sampath, 2006). These account for why some systems 
are able to perform and adapt to changing circumstances and demands better than 
others. In catching-up economies, despite the availability of a global stock of advanced 
technology to draw upon, systemic limitations like the availability of human capital, 
finances and scientific infrastructure can act as major limitations.4 Alternatively, 
catching-up economies that have been doing reasonably well in certain sectors may be 
facing a transition having reached a stage where their latecomer advantage is close to 
exhaustion, either due to technological or other factors, such as globalization and 
international trade rules (see for example, OECD, 2002). In such cases, affirmative policy 
and institutional support that aim at enhancing the effectiveness of the national 
innovation system will play a large role in securing firm-level competitiveness.  
 
In the pharmaceutical sector, India is often cited as an example of an “innovative 
developing country” with significant capacity to carry out health innovation.5 Indian 
generic firms are an important source of medicinal supply domestically and 
internationally, presently produce 22% of all generic drugs world-wide (Verma, 2005, p. 
436).6 The Indian pharmaceutical sector is undergoing a transition ushered in by a 
number of factors, intellectual property protection due to India’s full scale compliance 
with the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) 
and introduction of uniform standards for good manufacturing practices (GMPs) being 
two important ones. Appropriate innovation policy interventions can play a large role in 
cushioning this transition post-2005. Using firm level data collected in 2004-2005, this 
paper focuses on the Indian pharmaceutical sector to make two main points. Firstly, the 
Indian pharmaceutical sector is a very heterogeneous mixture of firms, from large scale 
                                                 
4  Economic catch-up is a process by which countries that are followers in technological terms, 
are learning through the acquisition of technological capabilities to catch up with the leaders 
(see Abramovitz, 1986; Amsden, 1989). 
5  “Innovative developing country”; a developing country that has demonstrated a significant 
promise in carrying out activities in health innovation (Morel et al, 2005, p. 2; Mashelkar, 
2005). 
6  Indian pharmaceutical firms produce 22% of all generic drugs world-wide and also actively 
supply vaccines (Verma, 2005, p. 436). The Indian vaccine market, estimated at 
approximately ~$150 million to 260 million USD, accounted for 57% of the total Indian 
biopharmaceutical output in the year 2002-2003 (Srinivas, 2006). 
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firms that are doing innovative research to firms that are seeking to specialize in niches 
in the drug discovery, development and production process to pure manufacturers. 
Based on the firm level data, the paper shows that the sector can be broken up into three 
groups of firms, each having a very different level of technological capabilities to 
conduct pharmaceutical innovation. The analysis also links the policy framework over 
the past four decades to the varying levels of capabilities of the three groups of firms, 
thereby clearly establishing the link between innovation policy and capabilities of firms. 
Secondly, the analysis highlights the point that innovation is not just R&D; a range of 
systemic factors, such as quality of infrastructure, collaborative linkages, skilled 
manpower are key to achieving innovative capabilities. These systemic factors 
determine whether firms move from being merely static to being self-generating or 
innovative. In making this point, this paper argues that the strengths of the sector that 
are reflected in India’s success stories (of a few firms) are not representative of the entire 
potential of the sector. The tendency to flaunt just the few success cases and ignore the 
laggards has to be avoided if India is to harness the strength of the sector as a whole, and 
not that of just a few successful firms. The need for differentiated policy support is 
highlighted. 
 
1.2. Data and Variables 
 
The data used in this paper was collected in a firm-level survey of the top 103 firms in 
the Indian pharmaceutical sector, ranked on the basis of their export potential, annual 
sales and R&D investment figures. The survey was conducted between October 2004 
and January 2005. An innovation system-oriented and policy-relevant innovation survey 
at the firm level is complex and not too many such surveys have been conducted in the 
pharmaceutical sector in India. In order to draw policy-relevant conclusions from the 
information gathered, the survey was specifically designed to focus on two key 
variables, namely, learning and innovation processes in Indian pharmaceutical firms 
and how these will be impacted by stronger intellectual property protection, which is an 
important instrument of innovation policy. 
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A background country report of the Indian pharmaceutical industry was first prepared 
to feed into the survey. A range of semi–structured interviews with experts in the area of 
pharmaceutical innovation and intellectual property rights were conducted as the 
second step in order to help clarify the structure and content of the survey and to 
provide content validation to the survey questionnaire. The questionnaire was then 
administered to the top 103 firms in an industry list created using data on export 
potential, R&D investments and annual sales from online databases on the Indian 
pharmaceutical sector, such as the India Infoline and Pharmabiz. Additionally, a total of 
forty five face-to-face interviews were conducted, with CEOs, heads of R&D and 
marketing of the companies that were surveyed. Some of the top governmental 
executives in the Ministries of Health, Industries and Commerce were also interviewed. 
 
The paper is structured as follows. Section 2 of the paper discusses the main phases of 
policy interventions in India over the past four decades that led to the building of 
technological capabilities in the sector. It shows how the nature of innovation in the 
sector is strongly linked to the emphatic thrust placed on developing local production 
technologies by the government, and also discusses the varying levels of capabilities 
between the three groups of firms as they stand presently. Section 3 looks at emerging 
innovation strategies, and section 4 uses empirical data to emphasize on how lack of 
systemic components affects product and process innovative capabilities amongst the 
three groups of firms. It brings forth two important points of relevance to policy; that 
there is a need for much more than R&D for the innovative firm to emerge and it also 
identifies the systemic factors that foster this transition, such as collaboration, 
intellectual property protection, presence of skilled manpower, venture capital and 
mobility of labour, that affect innovative capabilities. Section 6 concludes. 
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2. Structure of the Indian Pharmaceutical Sector 
 
The Indian pharmaceutical sector is amongst one of the largest within developing 
countries and is reported to have had an overall production value of US$ 7 billion in the 
year 2003 (IBEF and Ernst and Young, 2004a, p. 8).7 Presently, it is the second largest 
export industry in India, exporting to over a 100 countries in total. Its main export 
regions are USA, Western Europe, Asia (especially China) and the middle-east (see Gehl 
Sampath, 2006). India also has the largest amount of FDA approved drug manufacturing 
facilities outside of the USA (OPPI, 2003). The industry growth rate during the 1990s 
was on an average around 15% for bulk drugs and 20% for formulations (IBEF and Ernst 
and Young, 2004a). 
 
2.1. Main triggers and actors for innovation 
 
The pharmaceutical sector employs technological capabilities that are rooted in 
innovative drug discovery and development activities (product development), 
technological capabilities related to discovering different processes of producing drugs 
(process development), and finally, technology related to producing and packaging 
formulations (manufacturing) (Srinivas, 2004, p. 44). Certain limitations in the macro, 
meso and micro environment render it hard for developing countries to build these 
capacities in the pharmaceutical sector. At the macro level, a disjuncture between 
demand for health research and on-going activities in the sector, a lack of scientific 
culture amongst scientists and researchers (including emphasis on collaboration), weak 
public support and bureaucratic rigidity are some of the main problems that challenge 
the system (CHRD, 1990, p. 47). At the meso-level, there are issues of access to 
information and technological inputs that are important for health research, inadequate 
human capital formation, institutional instability and weak scientific infrastructure. And 
at the micro-level, issues of intellectual isolation of researchers and lack of incentives for 
collaborative research, such as low salaries, restriction of career opportunities due to 
                                                 
7  The IBEF (Indian Brand Equity Foundation) is a public-private partnership between the 
Ministry of Commerce, Government of India and the Confederation of Indian Industry (CII). 
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bureaucratic bottlenecks in adequate research budgets, and lack of on-job training 
possibilities make it hard to create an efficient innovative environment (Ibid.). 
 
Although India’s chosen path to achieve self-sufficiency in the sector was one of an 
“independent latecomer” (Amsden and Cho, 2003), the government’s main focus was on 
achieving local production of all antibiotics needed by the Indian population.8 From the 
1960s until now, policy changes that have had impact on the sector broadly belong to 
three identifiable phases.  
 
The first set of policy changes, mainly attributable to India’s socialist vision in the 1960s 
and 1970s, were instrumental in laying the fundaments of the sector. The setting-up of 
government-held companies to boost local pharmaceutical production of drugs, the 
Drug Price Control Order and finally, the Indian Patent Act of 1970, was accompanied 
by other policies to augment these major changes, such as restrictions on foreign direct 
investment (see Gehl Sampath, 2005a).  As a result of the changes introduced by the 
Patent Act, the number of patents granted per year within India fell by three quarters 
between the years 1970-71 and 1980-81 (Lanjouw, 1998, p. 4). The Drug Price Control 
Order acted as an added disincentive, by setting a ceiling on the overall profits of 
pharmaceutical companies. It was harshly criticized by multinational companies 
operating in India at that time on grounds that it will reduce the incentives for 
investments in the sector (Ramani et al, 2001). The criticism also found basis in reality: 
when the Order came into force, multinational companies operating in India lost interest 
in expanding their operations in the Indian market, which included R&D efforts, due to 
the low profit margins involved (Ibid). In order to boost local production of drugs, the 
main policy pursued by the government was to import the penultimate intermediate 
required for bulk drug manufacture, so that the last step of the reverse engineering 
                                                 
8  In India, the government’s vision to reduce dependency on multinational firms for drugs, 
especially antibiotics, was the starting point of building self-sufficient local production 
facilities in the pharmaceutical sector. The focus on antibiotics came from the predominant 
public health and ‘access to medicines for all’ perspective that ruled Indian thinking in the 
1950s and 1960s. This, in Amsden and Cho’s definition (2003), is a clear case of the 
“independents”, which are countries that invest heavily in their own technologies and 
national enterprises to generate proprietary cutting-edge skills (p. 2). 
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process could be conducted within India by local firms to produce active pharmaceutical 
ingredients (APIs). Technology required to enhance reverse engineering skills, 
specifically those related to imitative process R&D, formulation and production 
technologies was acquired through public sector efforts, and then passed on to the 
private sector (see for example, Srinivas, 2004). The local industry, a large part of which 
developed through spin-off entrepreneurship of employees of government-held 
pharmaceutical firms, were quick to take cue from the conducive environment: they 
developed extensive skills in chemistry-based reverse engineering which forms the core 
of their product and process development skills until today. Indigenous local capacity 
for production was thus built through a combination of the right policy environment, 
access to international technology, education and promotion of entrepreneurship, 
among other factors while the main impetus for learning came from learning-by-doing 
activities (Mashelkar, 2005). Over a period of time, even when the Price Control Order 
reduced its coverage in the 1980s and 1990s, the threat of reverse engineering by the 
local firms kept subsidiaries of multinationals operating in India from introducing new 
products in the Indian market.9 
 
This first phase of policy changes also included policies that targeted India’s higher 
education and health research spending, placing an extraordinary emphasis on science-
based university education and specialized public research institutes (PRIs). The 
government has been instrumental in investing in setting up excellent university 
education facilities in key disciplines of relevance to pharmaceutical research (such as 
                                                 
9  Several subsidiaries of multinational companies who were interviewed underscored the 
point that the ability of Indian forms to produce generic copies of successful drugs was a big 
factor in their lack of interest to introduce innovative drugs that had huge markets in other 
Western countries in India. Lanjouw (1998) presents several examples on this point – Indian 
companies were able to introduce copies of Ciprofloxacin within seven years of its 
introduction in India, Glaxo was similarly faced with several local competitors on the very 
day it introduced its drug Ranitidine (Zantac) in India (at p. 9). Even in the case of off-patent 
drugs, MNCs operating in India have been wary of Indian competence to replicate drugs 
and create price competition in the local market. A good case is that of Teramycin 
(Oxytetracyclin), a patent on which was held by Pfizer that expired in the 1960s. Despite the 
expiry of the patent, Pfizer did not want to share the know-how with Indian companies, for 
fear of strong price competition in the local generics market. Dr. Sarabhai Laboratories, the 
first Indian firm to produce Tetracyclin, did so through reverse engineering skills (Pers. 
Comm, D.G. Shah, 13 January 2005). 
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those in medicine, pharmacology, chemistry, biochemistry, biology, molecular biology 
and biotechnology among others), as well as set up public research institutes such as the 
Centre for Science and Industrial Research (CSIR), Indian Drugs and Medical Research 
Institute (IDMR), All India Institute of Medical Sciences (AIIMS), Indian Institute of 
Chemical Technology (IICT), Indian Institute for Science (IISC) among others. This trend 
has continued well into the present, with institutes such as the Institute for Human 
Genetics, the Centre for Biotechnology, Institute of Microbial Technology all being 
established with the mandate of conducting research on emerging areas of importance to 
drug research. Throughout the past four decades, governmental spending on health 
research has been extensive, with up to 90% of all research funds being sourced 
internally for both the public and private sector (CHRD, 1990, p. 49).10 The creation of 
extensive scientific infrastructure and skilled human capital that can be absorbed into 
the sector, coupled with a regulatory environment that expressedly encouraged 
learning-by-copying and learning-by-doing meant that Indian firms thrived and 
invested into several kinds of generic activities. They branched out from just importing 
the bulk drug in its penultimate form, to importing raw materials and creating bulk 
drugs themselves, and into formulations business in a big way (Srinivas, 2004). 
 
A second phase of policy changes was triggered off by India’s trade liberalization in the 
end of the 1980s. By this time, the pharmaceutical sector was exporting bulk drugs and 
formulations, and was recognized to be of strategic importance due to its technological 
and export potential. Several of the policy changes undertaken in this phase were aimed 
at enabling the sector take advantage of India’s shift from an import-substitution 
economy to a liberalized one, and helped boost the potential of the sector as an exporter 
of generic formulations. This, supported by India’s continuing minimalist IPR regime 
created a comfortable and stable economic climate where several of the larger firms, like 
Ranbaxy and Dr. Reddy’s ventured out to acquire facilities in developed countries in the 
1990s (for example, the USA).  
 
                                                 
10  A 1986 cross-country comparison of several developing countries including Brazil, Mexico, 
Philippines, Thailand, and India ranked in the top category of government spenders for 
health research within developing countries (CHRD, 1990, p. 49). 
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These two phases of policy transformations were responsible for the radical changes in 
the foreign versus local firm ratio in the Indian market. From a virtually non-existent 
domestic sector in 1970 (15% of Indian firms as against 85% foreign firms in the local 
market), the market structured transformed into one where both Indian and foreign 
firms held a 50% share in 1982, to a 61% Indian and 39% foreign share in 1999 (OPPI, 
2000). From 2001 onwards, eight out of the ten top firms in the sector are Indian firms 
and only two are subsidiaries of multinational companies (Business World, 2006). Indian 
firms also hold a local market share of 75%, and the sale of retail formulations in the 
domestic market reached an estimated US$ 4.3 billion in the fiscal year 2003 (IBEF and 
Ernst and Young, 2004a, p 8). 
 
In the present context, the main actors in the Indian innovation system are: 
• Government-held companies and private companies, spread across a wide range 
of specializations, chemistry based pharmaceutical formulations, clinical research 
and testing and biotechnology 
• Governmental agencies especially under the umbrella of the Ministry of Science 
and Technology, Ministry of Health and the Ministry of Industries, Trade and 
Commerce. 
• The Organization of Pharmaceutical Producers of India (OPPI), the Indian 
Pharmaceutical Alliance (IPA) and the Indian Drug Manufacturers’ Association 
(IDMA).11 
• Public research institutes such as the CSIR, IDMR 
• Hospitals and medical service agencies, especially training hospitals 
• The traditional medicinal sector 
 
A third phase of policy changes is presently underway, having been triggered off by 
India’s compliance to the Trade Related Aspects of Intellectual Property Rights (TRIPS 
Agreement). India has changed its intellectual property regime for pharmaceutical 
products radically between 1999 and 2005, becoming fully TRIPS-compliant in 2005 with 
                                                 
11  There are also other associations that are active in representing pharmaceutical companies in 
India, but these are comparatively smaller and therefore have not been mentioned here. 
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the grant of product patent protection. The changes induced by intellectual property 
protection will be profound, because they are accompanied by potential losses to the 
sector since generic versions of drugs that are patented elsewhere can no longer be 
produced by Indian firms (see Fink, 2000, Cheri, 2004 and 2005; Gehl Sampath, 2005a). It 
has also been accompanied by several other changes aimed at enhancing the industry’s 
credibility nationally and internationally, one such change being the introduction of 
good manufacturing practices (GMPs) applicable uniformly across the sector. 
2.2. Nature of innovation and firm groups in the Indian pharmaceutical sector 
 
The Indian pharmaceutical sector is a heterogeneous mixture of firms, both organized 
and unorganized (Ramani, 2002). They range from large firms that are either 
subsidiaries of large multinational firms or wholly Indian, such as Cipla, Ranbaxy and 
Dr. Reddy Labs, to medium and small-sized firms that also extend to garage operations. 
As against the commonly quoted figure of 20,000 manufacturing units in the 
pharmaceutical sector,12 an expert committee set up by the government of India in 2003 
has clarified the number of active units on the basis of drug manufacturing licenses 
issued (Expert Committee, 2003, p. 3). According to the Committee, the total number of 
manufacturing units engaged in the production of both bulk drugs and formulations 
within India is not more than 5877.13 The market is highly fragmented with only around 
300 companies accounting for almost all of the domestic market. 
 
The 6000 odd firms that form part of the sector demonstrate significant technological 
differences that reflect in their annual sales turnover, export potential, R&D investments 
and most importantly, the nature of innovative activities. Using country level data 
collected on these variables, the firms can broadly be classified into three main 
categories.14 The first group of firms (hereafter, group 1) comprises large-scale 
                                                 
12  See for example, CII (1999), which quotes 18,000 small-scale units and 250 large-scale 
companies in the Indian pharmaceutical sector. 
13  This can be further broken up into 1333 bulk drug units, 4534 formulation units, 134 large 
volume parenteral units and 56 vaccine-manufacturing units. 
14  I thank Mr. Dilip G. Shah, President, Indian Pharmaceutical Alliance for taking out the time 
and helping me to organise the secondary and primary data to arrive at this classification. 
 17
pharmaceutical firms that are both subsidiaries of MNCs in India or wholly-owned 
Indian firms. Group 1 includes firms like Ranbaxy, which is the largest pharmaceutical 
company in the country, also ranked in the top 100 companies worldwide; Cipla, which 
is the largest producer of generic drugs in India with around 800 products in the market 
(Interviews). Group 1 firms have an annual sales turnover of more than 300 crore rupees 
(US$ 650,000), have extensive brand marketing networks for their brands that help in 
creating and promoting brand identity of their products amongst consumers across the 
country. The second group of companies (hereafter, group 2) comprises medium sized 
operators who are either generic producers or specialists in niche areas of contract 
research and small scale units which manufacture drugs for the bigger firms within 
India. These companies supply predominantly to the Indian market as well as to other 
semi-regulated and unregulated markets. Firms classified as group 2 have an annual 
sales turnover between 100-300 crore rupees (US$ 210,410 to US$ 650,000). The third and 
final group of companies (hereafter, group 3) comprises those that mainly perform 
manufacturing activities for bigger Indian companies, both local and multinational 
companies. Companies that fall into group 3 have an annual turnover of less than 100 
crore rupees (US$ 210,410) annually. The 6000 odd firms can be broken up into 100 firms 
belonging to Group 1, 200 firms to group 2 and the remaining 5700 fall into group 3, 
when both bulk drugs and formulations are taken into account (Gehl Sampath, 2005a, p. 
27). This categorization helps pin point the extreme variance in industry structure 
because it embodies the vast differences amongst firms in terms of firm size, 
employment capacity, innovation potential, R&D investments and exports. Out of the 
103 firms surveyed as part of the empirical investigation, 31 belonged to group 1, 27 to 
group 2 and 44 to group. 
 
3. The Innovator, the Niche-Operator and the Manufacturer: Different Innovation 
Modes?  
 
Group 1 comprises mainly of big pharmaceutical firms, whose pharmaceutical activity 
can be classified into two main categories: generics and innovative R&D. These 
‘innovative’ firms already have large market shares domestically, and are supplying to 
regulated, semi-regulated and non-regulated markets. Their R&D activities mainly 
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focused on process development until recently and the R&D expenditure of the 
companies is presently around 6% of their annual turnover, and this is projected to rise 
up to 10% by the year 2010.15 Extensive process development capabilities have enabled 
these firms to venture into innovative options, such a specialty generics, and the firms 
are keenly developing marketing infrastructure abroad to penetrate foreign (regulated) 
markets. This has been the driving force behind the recent wave of international 
acquisitions and alliances such as Dr. Reddy’s acquisition of Betapharm in Germany (the 
4th largest generic company locally), Ranbaxy’s acquisition of RPG Aventis in France 
(amongst the top five generic companies) and Terapia in Romania, and Matrix 
Laboratories acquisition of DocPharma in Belgium (the second largest generic company 
locally) (Krishnan, 2006a, p. 48). The experience of group 1 companies has been that 
while the entry barriers to regulated markets for the supply of generics are very high, 
the monetary returns and the ease of business that follows entry into these markets are 
both higher than in the semi-regulated and unregulated markets worldwide. These 
added profits earned by the sale of generic products in regulated markets allow group 1 
firms to increase their R&D spending locally. 
 
Group 2 companies have an annual turnover between 100-300 crore rupees and have 
much more limited investment capabilities to indulge in R&D. They are either pure 
generic suppliers, or are shifting to product development categories that involve 
specializations. Companies in group 2 are trying to establish themselves as niche players 
in contract research and manufacturing by choosing specific areas where they can be 
competitive. Some of these companies that are quite high up in the profitability chain 
presently are also planning to expand their activities and gradually move into regulated 
markets following the example of group 1 companies, thereby climbing up the industry 
value chain.  
 
The activities of both group 1 and 2 companies show that R&D efforts and process and 
product innovation are not isolated phenomena in the Indian pharmaceutical sector as 
projected by many scholars, but well inter-linked. Adaptive and incremental innovation 
                                                 
15  See Srinivas (2004) in this context, who notes similarly that the emphasis of even the very big 
firms such as Ranbaxy, Cipla, Cadila was mainly on antibiotics production until recently.  
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activities are non-trivial activities. Reverse engineering, for instance, presupposes a deep 
understanding of the processes and products in the pharmaceutical industry. As Kline 
and Rosenberg (1986) observe, quite often design is the initiating point of innovation. 
What Indian firms have been doing falls clearly in this domain. They further note that 
innovation has three major aspects to it: (a) innovation is not a linear process but one 
involving many interactions and feedbacks in knowledge creation; (b) innovation is a 
learning process that involves several inputs at the same time; and lastly, (c) on-going 
innovation processes can be initiating factors to invention processes that involve formal 
R&D (Kline and Rosenberg, 1986). This observation too fully applies to the pattern of 
expanding R&D activities of Indian firms. Despite the emphasis on generic filings in 
regulated markets to secure higher revenues and the edge in process development, focus 
on original product development activities is gradually increasing within the sector. 
Several large companies are very good examples of this, but there are also other 
medium-sized companies that are moving into niche operations for exports mainly, 
which help emphasize this transition in the Indian pharmaceutical sector. Their 
strengths in process development and manufacturing are helping to adopt a 
combination of cooperative and competitive strategies, in order to adapt and as well as 
capitalize on opportunities created by the new TRIPS-compliant patent regime. 
 
Group 3 companies, contrary to popular misconceptions; are mainly threatened by the 
standards on minimum GMPs introduced under the new Schedule M of the Drugs and 
Cosmetics Act. This will be the main reason, and not product patent protection, that will 
force unviable units to close down in this group subjecting it to maximum consolidation 
in the next decade. Although many of the group 3 firms are also strategically aiming to 
benefit from contract manufacturing, either for larger Indian firms or even for foreign 
firms post-2005, only those who can upgrade their plants to at least the GMP standards 
contained in the Schedule M of the Drugs and Cosmetics Act will tend to benefit. Even 
such a generalization has to be made with a note of caution, since the standards 
contained in Schedule M of the Indian Drugs and Cosmetics Act are much below the 
WHO standards on GMPs. In this context, it remains unclear as to whether group 3 
companies that do upgrade their facilities to the standards specified under Schedule M 
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can indeed target contracts for manufacturing from MNCs/ firms operating outside 
India. In order to be able to manufacture for foreign partners from regulated markets, 
standards of foreign inspectors such as USFDA will need to be met by group 3 firms, 
which are much more stringent than both the Indian and WHO standards on GMPs. It 
therefore seems more likely that most such companies which do adhere to GMP 
standards as specified by Schedule M will perform contract manufacturing for group 2 
companies in India who are looking at filling in the demand for generics in the 
unregulated and semi-regulated markets or foreign partners directly from the 
unregulated and semi-regulated markets. Alternatively, group 3 companies that comply 
with Schedule M will also supply to companies that are targeting the domestic Indian 
market. 
 
Tables 1 and 2 below have a list of emerging strategies amongst firms in the three 
groups. As the tables go on to show, the ‘innovative’ firms in group 1 are using the 
revenues they derive from the sale of generics in regulated markets to move higher up 
into the R&D chain. Group 1 companies in India are therefore choosing a mix of 
cooperative and competitive strategies to deal with challenges and opportunities post-
2005.16 Although Indian companies acknowledge that producing the next blockbuster 
new chemical entity (NCE) is still some way off for them, their competitive and 
collaborative strategies are centered around increasing internal technological 
competitiveness and securing higher revenues from more sales in regulated markets (by 
tapping the marketing networks of the non-Indian partners) to invest higher amounts 
into innovative R&D. Their R&D strategies include the development of non-infringing 
processes, biopharmaceutical research and drug discovery and development, either in-
house through analogue research strategies (research that focuses on finding new drugs 
within a family of molecules where useful drugs have already been discovered) or by 
offering drug discovery services. Out-licensing strategies (identifying a number of new 
compounds that are likely to work, takes them until the pre-clinical stages and then 
                                                 
16  This is mainly applicable to the Indian firms in Group 1. The subsidiaries of MNCs that 
belong to this group are also planning to expand operations or entering into collaborative 
arrangements, but are waiting to see progress under the Indian Patent (Amendments) Act, 
2005. 
 21
strikes a deal for clinicals with a MNC) are also becoming common. On the generics 
front, they continue to venture deeper into specialty generics17 and novel drug delivery 
systems (NDDS)18 and production of biogenerics in order to increase their revenues from 
regulated markets (Interviews; IBEF and Ernst and Young, 2004a, p. 11; see Table 2 
below). Their marketing strategies are geared towards using their marketing prowess to 
market newer drugs in the Indian markets (co-marketing alliances with MNCs), and 
mergers and acquisitions in foreign markets to tap into a greater share of the market in 
the EU and USA. 
The firms in group 2 qualify to be called niche-operators because they are slowly 
moving into areas of clear specialization in the drug discovery and development value 
chain. There is an enormous emphasis being laid upon specialized contract research the 
areas of clinical research, drug discovery, non-infringing process development and the 
manufacturing of biogenerics. Several group 2 companies specialize in developing non-
infringing processes for drugs. Apart from Strides Acrolab India, another group 2 firm 
that has been a huge success and has even moved into group 1 in a really short span of 
six years is Matrix Laboratories.19 Avaant Pharmaceuticals’ main focus is to secure drug 
development licenses for compounds that were discovered by global pharmaceutical 
firms, but subsequently ignored either due to research difficulties, change in R&D focus 
or management changes in the company. Avaant presently has licenses for drug 
development from several big companies, like Bayer (Krishnan, 2006c). Several other 
group 1 companies are themselves setting up niche R&D centres as standalone 
organizations, such as the new R&D centre set up by Sun Pharmaceuticals, called Sun 
Pharma Advanced Research Company (Krishnan, 2006b). There are others who are 
seeking to specialize in generics business, focusing their attention on the business 
opportunities created by the shift of group 1 firms into regulated markets and 
innovative drug research. Several group 2 firms are actively supplying off-patent 
                                                 
17  Speciality generics are generics of reformulated older molecules, but made using new drug 
delivery technologies. 
18  Specialty generics are generics of reformulated older molecules, but made using new drug 
delivery technologies. 
19  Matrix Laboratories, a firm specializing in developing non-infringing processes, is now 
ranked as the 13th best pharma company in India (Business World India top 500 Rankings, 3 
April 2006). The firm has moved on from being a group 2 company into a group 1 company 
in a short span of six years. 
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generics to the semi-regulated and unregulated markets, by setting up manufacturing 
plants outside India or strengthening supplier partnerships. Ajantha Pharmaceuticals is 
a good example: apart from having a big presence in Russia, it has set up a 
manufacturing plant in Ukraine and is seeking gradual entry into regulated markets. 
In contrast to such accounts, group 3 firms are not exactly making headlines, since their 
activities are basically geared towards surviving by upgrading their manufacturing 
facilities, and continuing to manufacture to either supply to big manufacturers within 
India, or directly export to unregulated markets in Africa. Most of these firms are 
struggling to cope with changes to status quo, although learning continues in those who 
manage to upgrade their production activities, hence qualifying to be called 
‘manufacturers’. 
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Table 1: Emerging firm strategies: a categorization20 
Firm group Drivers Emerging R&D Strategies Positive effects of the transition 
Group 1  
Innovators 
• Entry and establishment in 
regulated markets 
• Higher gains from sale of products 
in regulated markets 
• Pressure to strengthen product 
portfolios to be able to compete 
internationally 
• Greater investment into innovative 
R&D using revenues earned by 
product sales in regulated markets 
• Increase science-based in-house 
infrastructure, with highly qualified 
staff 
• Greater innovation in generics; new 
products and processes. 
 
• Intellectual property rights. 
• Collaborative arrangements with 
foreign firms for R&D as potential 
technology sourcing and learning 
opportunities. 
• Boost to already strong local/ 
regional marketing networks through 
co-marketing alliances with foreign 
firms. 
Group 2 
Niche 
operators 
• Increased sales in semi-regulated 
and unregulated markets due to the 
shift in focus of group 1 companies 
to regulated markets 
• Pressure to strengthen competitive 
advantages, to make use of 
opportunities such as CRAM in the 
new environment 
• Active supply of off-patent generics 
to the semi-regulated and 
unregulated markets 
• Focus on establishing themselves as 
niche players for contract research by 
choosing specific areas that give them 
competitive advantage: e.g., clinical 
research. 
• Moving up the industry’s value chain 
gradually. 
• Intellectual property rights 
• Contract R&D and collaborative 
arrangements with foreign firms for 
R&D as potential technology sourcing 
and learning opportunities. 
• Opportunities to occupy the semi-
regulated and unregulated markets, 
and also follow group 1 firms into 
regulated markets 
Group 3 
Manufacturers 
• Survival in the light of Schedule M 
of the Drugs and Cosmetics Act and 
India’s full fledged TRIPS 
compliance 
• Upgrading facilities to Schedule M 
standards in order to continue 
manufacturing for group 1 and 2 
companies. 
• Move up the industry’s value chain 
through upgrading production 
technology. 
Source: WHO-INTECH survey conducted by author, 2005 
 
                                                 
20 Sridharan (2005) presents a similar categorization of the industry split into three main groups: the innovator, the collaborator and the 
endangered. 
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Table 2: Collaborative and Competitive Strategies of Group 1 Firms 
Competitive strategy: Indian generics in  regulated markets  
A favoured strategy of top Indian generic companies has been to challenge patents on 
blockbuster drugs in the US market, and get a 180 days Exclusive marketing right (EMR) to 
launch their generics by filing early. According to US laws, the generic company that wins such 
a challenge can hold a 180 day EMR, if it was the first-to-file for marketing approval. Dr. 
Reddy’s early win of the 180 day exclusivity of Prozac when it went off patent in the US market 
set this trend. But not only have Indian generic companies not won a single EMR since then, cut 
throat generic competition and the strategy of granting ‘authorized’ generics by US companies 
have meant a series of losses for firms like Ranbaxy and Dr. Reddy’s in recent times. Dr. 
Reddy’s challenge of Eli Lilly’s Zyprexa (a $ 2.6 million drug that went off patent) in 2004 and 
Ranbaxy’s challenge of the Pfizer drug Lipitor (a $8 billion drug that went off patent) in 2005 
failed, in addition to which prices of drugs like ciprofloxacin that both companies introduced in 
the US market crashed to 80% within weeks due to the presence of too many generic companies. 
Only recently, Ranbaxy has again won another EMR for a 80 mg generic dosage of the statin 
Zocor (a Merck patent, with sales of $ 4.3 million) and Ranbaxy is awaiting its EMR for the 80 
mg dosage of Pravastatin. Yet, the new strategy seems to be to combine securing EMRs which 
bring in huge profits, with launching generics even when there is no EMR. This may mean that 
profits per generic launched are lesser since Indian firms will be competing with several others 
in the US market supplying similar generic versions, but can still be a huge grosser since there 
are about 40 drugs going off patent between 2006 and 2008 (with a total worth of US$ 50 billion). 
Firms are also trying to secure licenses as “authorized” generic producers for US companies, 
instead of constantly competing with other generic companies that get “authorized” to produce 
the drug from the original patent holder company. They are also exploring partnerships to 
jointly contest and introduce generics with other top generic companies, such as Teva. Ranbaxy 
and Teva recently launched the drug Quinapril jointly, based on a successful EMR that Ranbaxy 
contested and won in the USA.  
Collaborative strategy: out-licensing research 
Another commonly used strategy is to identify a number of new compounds that are likely to 
work, work on them until the pre-clinical stages and then license them out to foreign firms for 
clinical trials. Several molecules have been out-licensed by Indian firms for clinical trials 
presently. Ranbaxy has identified 11 compounds in the categories of infectious respiratory, 
urinary disease, and diabetes categories, of which 2 are presently in Phase 1 trials. Dr. Reddy’s 
Labs has identified 37 promising compounds in cardio vascular, diabetes and cancer categories 
of which 9 are in Phase 1 and 2 trails. Similarly, Wockhardt has two compounds in clinical trails 
which are in the flouroquinolines category, but are believed to be antibiotics that work in the 
new drug-resistant categories of infections. 
Collaborative strategy: Discovery services out-sourcing 
The term refers to services that support drug discovery and help test efficacy of a potent 
molecule. Recently, GVK Biosciences and Wyeth USA have entered into a contractual agreement 
whereby GVK Biosciences will set up a R&D centre on its campus in Hyderabad and hire 150 
scientists exclusively before the end of 2007 to work on drug discovery projects for Wyeth. 
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Similarly, Jubilant Organosys and Eli Lilly have a contractual arrangement on which 100 
scientists within Jubilant will work solely for Eli Lilly’s drug discovery programmes. 
Source: Krishnan, 2004; 2006a, p. 46-48; 2006b; 2006d  
 
Data gathered in the survey corroborated this categorization of innovative activities and 
R&D spending. Although the percentage of annual sales turnover that is spent on R&D 
by all three groups is quite low (less than 10%), it has increased notably since 2000 (see 
Table 3). Group 1 firms that were surveyed spent 8.09% of their annual sales on R&D in 
2004, as compared to 5.15% in group 2 and 7.74% in group 3. Whereas the amount 
indicated by groups 1 and 2 clearly represent their respective activities, the figure for 
group 3 needs to be clarified. The amount is indicative of the investments that group 3 
firms are making on upgrading their manufacturing facilities and enhancing their 
process technologies. 
Table 3: Group-wise R&D and exports 
Variable Group 1 
Mean 
Group 2 
Mean 
Group 3 
Mean 
R&D intensity in 2000  3.4 (0.042)* 1.3 (0.041) 5.3 (0.072) 
R&D intensity in 2001        4.4 (0.063) 2.8 (0.067) 6.5 (0.095) 
R&D intensity in 2002 6.7 (0.066) 4.2 (0.076) 7.4 (0.100) 
R&D intensity in 2003 7.3 (0.064) 4.6 (0.080) 7.8 (0.104) 
R&D intensity in 2004 8.1 (0.073) 5.2 (0.090) 7.7 (0.088) 
Non R&D performers 12.9 (0.341) 34.6 (0.485) 26.1 (0.444) 
Exporting firms 83.9 (0.374) 73.1 (0.452) 56.5 (0.501) 
N 31 26 46 
*Standard deviation 
R&D Intensity = percentage of total sales spent as R&D 
Source: WHO-INTECH Study conducted by author 
 
4. The role of policy interventions in sectoral performance: major challenges  
 
Much more than just R&D investments go into making an innovative firm. But since the 
emphatic focus of policy changes was on encouraging the local production of drugs at 
affordable prices and not on building an innovative sector until the 1980s, policy action 
has resulted in a strange assemblage of strengths, and significant differences in 
technological capabilities of firms in the sector. These strengths are reflected in the way 
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the sector has been able to thrive beyond mere production of generics into innovative 
territories, expand and tap into modern technologies like health biotechnology. These 
strengths, albeit promising, are challenged by the many shortcomings that the 
innovation system presently suffers from. Clearly, the first phase of policy changes were 
the ones that had a definite impact in shaping the nature of pharmaceutical activity and 
sectoral growth. Their impact was pervasive; even today the main strengths of firms 
belonging to all three groups are in anti-infectives, including companies like Ranbaxy, 
Cipla, Dr. Reddy’s, although group 1 companies have diversified into other segments 
(Srinivas, 2004, p. 51). Although the other two phases of policy changes also have been 
important for the sector, they were not as well-coordinated and dynamic, and their 
impact was not as profound as the first set of changes. The successes of Group 1 and 2 
firms today are not attributable to a well-coordinated innovation policy for the sector, 
but rather, stimuli to innovation activities have come from several factors acting in 
tandem. The government’s continued support in the form of investments into good 
quality higher education in relevant disciplines, and very sophisticated scientific 
infrastructure to carry out pharmaceutical research has played a large role in the way the 
sector has been able to thrive. India’s liberalization has paved the way for lower 
governmental interference on export and imports, foreign exchange issues, apart from 
guaranteeing market based institutions. These have helped the growth of venture capital 
and external finance institutions and enabled firms sharpen up market-based, 
entrepreneurial skills, all of which group 1 and 2 firms are using to their advantage. 
The biggest failing of the policy process has been the neglect of the dynamic evolution of 
the sector and its activities from a production-based sector to an innovation-based one. 
This is reflected in the failure of policies to target enhanced systemic coordination and 
collaboration. When this reality is juxtaposed against emerging strategies of firms, three 
points stand out. Firstly, the wide range of strategies that Indian firms are choosing in 
order to gain and compete in the new environment unanimously underpin the 
importance of systemic factors, such as collaboration, intellectual property protection, 
skilled manpower and venture capital to facilitate the scale up from a “static” firm to a 
“surviving” or “self-generating” firm to an “innovative” firm. Group 1 firms who are 
innovating in the present environment could perhaps perform better if these elements 
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were present, but more importantly, the systemic factors discussed here will definitely 
affect how many firms in groups 2 and 3 make the transition to innovative activities. 
Finally, accounts of how the Indian pharmaceutical sector is thriving have a tendency to 
flaunt just the few success cases and ignore the large majority of firms in group 3 which 
are adrift with challenges of surviving in the present environment. In this section, both 
descriptive statistics and econometric analysis based on the empirical data have been 
discussed to substantiate these points. 
 
4.1. Factors promoting new product/ process innovations 
 
Table 4 below contains the responses of firms in each group towards various policies 
and how important they are for promoting innovation. The figures presented represent 
the mean in an interval between 0 and 1, where 0 is unimportant and 1 is extremely 
important. Therefore, any response above 0.5 indicates that the particular set of policies 
is important to promote innovation. 
 
Table 4: Contribution of factors in promoting new product/ process innovation 
Variable Cluster 1 
Mean 
Cluster 2 
Mean 
Cluster 3 
Mean 
Innovation incentives by 
the government 
0.387 (0.495)* 0.462 (0.508) 0.304 (0.465) 
Skilled manpower 0.935 (0.250) 0.923  (0.272) 0.891 (0.315) 
R&D collaboration with 
universities 
0.613 (0.495) 0.423 (0.504) 0.630 (0.488) 
R&D collaboration with 
PRIs 
0.581 (0.502) 0.385 (0.496) 0.522 (0.505) 
IPR protection 0.839 (0.374) 0.577 (0.504) 0.739 (0.444) 
Quality of infrastructure 0.903 (0.301) 0.962 (0.196) 0.739 (0.444) 
Venture capital 
availability 
0.839 (0.374) 0.808 (0.402) 0.630 (0.488) 
Local SMI participation 0.645 (0.486) 0.385 (0.496) 0.435 (0.501) 
Govt. firm tech. transfer 0.548 (0.506) 0.345 (0.485) 0.370 (0.488) 
Transfer of personnel 0.839 (0.374) 0.423 (0.504) 0.500 (0.506) 
Other policies 0.000 (0.000) 0.038 (0.196) 0.000 (0.000) 
Govt subsidies 2000-2005 0.258 (0.445) 0.269 (0.452) 0.130 (0.341) 
N 31 26 46 
*Standard deviation 
Source: WHO-INTECH survey conducted by author 
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The responses in the table show that whereas government incentives are not considered 
important by firms belonging to all groups, skilled personnel, IPR protection, quality of 
infrastructure, venture capital availability, and mobility of labour between firms, 
universities and research institutes were ranked to be very important factors in 
promoting both product and process innovation. 
 
4.1.1. Intellectual property protection and innovative capabilities 
 
All the firms surveyed rated intellectual property as an important factor affecting 
process and product innovations. It was thought to be very important by firms 
belonging to group 1 (0.839) and group 3 (0.739), and as being moderately important by 
group 2 firms (0.577) (see Table 4). Patenting activities have clearly been on the rise in 
India, accompanied by a growing realization that it is a primary factor in leveraging 
global competition to their advantage. Almost all group 1 and some group 2 firms are 
keen to secure intellectual property protection on their innovative efforts, wherever 
possible. Several models of intellectual property protection seem to be emerging, 
depending on the kind of innovation services being offered. Some firms, like Matrix 
Laboratories and Cipla are pursing defensive patenting strategies (See Gehl Sampath, 
2005a). Matrix’s main research focus is on developing non-infringing propriety 
processes for the production of APIs, in order to establish its position as a global 
supplier of APIs to major generic companies in regulated markets. Their intellectual 
property strategy is to acquire (ring fence) mostly all proprietary technologies that are 
needed for their alternate processes. Other firms that are branching out into product 
development like Biocon, are keenly looking at joint intellectual property ownership on 
such products with the company that originally discovers the successful compound 
(Hari, 2006a). For several specialized Indian firms, their value is increasingly getting 
associated with the value of the intellectual property they own. For example, intellectual 
property assets are key to Avaant Pharmaceuticals since it specializes in drug 
development using promising molecules from other firms (Krishnan, 2006c). Group 1 
and 2 firms also fear that intellectual property protection will adversely affect their 
ability to access new technologies (Gehl Sampath, 2005b).  
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Group 3 firms view intellectual property rights as equally important, but from a 
completely different perspective. For this group of firms, intellectual property and 
India’s TRIPS compliance is synonymous with severe losses due to escalating industry 
standards for manufacturing (GMPs). Several group 3 firms are also very vary of 
changes in industrial organization of the sector, owing to the entry of foreign firms, and 
fear negative impacts. There is also a tendency amongst group 3 firms to wrongly view 
the possibility of securing compulsory licensing for producing patent protected drugs as 
a venue of profit-making, since group 1 and 2 firms will now no longer be able to 
produce generic versions of patent-protected drugs freely (see Gehl Sampath, 2006). 
 
4.1.2. Infrastructure, skilled manpower and venture capital availability 
 
Firms also rate the quality of infrastructure, venture capital availability and availability 
of skilled manpower as very important factors that affect both process and product 
innovations. Venture capital climate in India is generally good, and is helping firms 
come up with innovative ways of adding value to pharmaceutical innovation 
(Economist, May 2006). Indian venture capital firms, although cautious, are supporting 
several novel ventures. Initiatives that could be considered risky such as Connexios 
(India’s first pure drug discovery company) and Health Care Global (a joint venture 
between a network of cancer care centres and a pharma biotech company specializing in 
cancer cure (Triesta Sciences)) have been funded in India (Hari, 2005; 2006b). Data 
collected also reveals that group 2 companies are most dependent on venture capital and 
equity markets whereas group 1 tends to also rely on more traditional sources such as 
banks and family funds. This is because some of the large group 1 companies are family-
run enterprises (Dr. Reddy’s for example).  
 
Companies in all three groups acceded to the benefits of infrastructure, scientific and 
general, there was a clear consensus that the government policies of setting up 
technology parks, public research institutes and investing in education have all been 
extremely useful for the sector. Group 1 and 2 firms that were interviewed also admitted 
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to having had a lot of success in attracting talented Indian diaspora to work in their 
companies especially onto their R&D teams (interviews). But there seems to be a need to 
revise/ restructure course outlines or even introduce completely new courses to meet 
industry needs for skilled manpower (field interviews with group 1 and 2). For example, 
most Indian universities do not offer clinical research as a course in Chemistry and 
Pharmacology, as is the case in countries like the USA and UK (Krishnan and Kamath, 
2005). There were only three institutes offering clinical research training in India as of 
2005, and none of these had been certified by a governmental body (ibid.). As a result, 
companies venturing into newer areas of research compete intensely for skilled 
personnel, and in most cases, organizations involved in areas like clinical research end 
up having to train research associated themselves (ibid.)  
 
4.2. Collaborative linkages and innovative capabilities 
 
The vertically integrated, in-house research oriented, pharmaceutical firm is now passé: 
no company has all the competencies required for a vertically integrated drug discovery 
and development program employing new technologies. Not only does this hold for 
India too, but also each one of the strategic option for innovative R&D lay a definite 
emphasis on enhanced collaborations with other organizations, each contributing 
through specialization. India is still lagging behind on several strengths required for 
drug discovery and biopharmaceutical research. Recent experiences of firms show how 
expanding from a chemistry base into newer areas can prove formidable. For example, 
firms are gradually discovering that only having trained chemists is not sufficient, 
developing excellence in clinical research requires personnel who have a thorough 
knowledge of good clinical practices, and are conversant in complex chemical synthesis 
(Krishnan and Kamath, 2005).  
 
But despite its obvious public health emphasis, India has for a long time not been able to 
promote very effective collaborative linkages between the different components in 
pharmaceutical innovation. Feedback of local demands for products into the research 
system is quite low, and this is getting more acute with time since firms tend to devise 
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export strategies more in keeping with export demands (Gehl Sampath, 2005a). 
University and public research institutes lack incentives to commercially orient their 
research. The old time practice of sourcing useful technologies for the private sector 
through the public research institutes has forged good linkages between PRIs and firms, 
which continue well into the present.  
Table 5 below contains a group-wise collaboration intensity index of the firms that were 
surveyed. The figure presented represents the mean in an interval between 0 and 1, 
where 0 is no collaboration and 1 is high level of collaboration. Therefore, any response 
above 0.5 indicates that collaboration is moderately important. As the table shows, firms 
in all three groups ranked collaboration intensity as low with all systemic actors (there is 
no rating above 0.5). 
Table 5: Collaboration intensities of firms 
Variable Group 1 
Mean 
Group 2 
Mean 
Group 3 
Mean 
Coll. with PRIs   0.323 (0.475)* 0.308 (0.471) 0.174 (0.383) 
Coll. with Industrial 
associations 
    0.452 (0.506) 0.308 (0.471) 0.348 (0.482) 
Coll. with universities 0.355 (0.486) 0.308 (0.471) 0.174 (0.383) 
Coll. with private labs 0.484 (0.508) 0.231 (0.430) 0.261 (0.444) 
Coll. with others 0.097 (0.301) 0.038 (0.196) 0.043 (0.206) 
Local collaboration 0.548 (0.506) 0.423 (0.504) 0.370 (0.488) 
Local extram. R&D 0.161 (0.374) 0.115 (0.326) 0.130 (0.341) 
Foreign Extram. R&D 0.226 (0.425) 0.077 (0.272) 0.043 (0.206) 
N 31 26 46 
* : standard deviation 
Source: WHO-INTECH survey conducted by author 
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The two-limit tobit estimates for collaboration of firms are reported in Table 6 below.  
Table 6: Two-limit tobit estimates: collaboration variables 
Variable coefficient (Std Err.) 
Productivity growth 
Coll. with PRIs in cluster 1 0.495* (0.243) 
Coll. with PRIs in cluster 2 -0.269 (0.224) 
Coll. with PRIs in cluster 3 0.042 (0.121) 
Coll. with Indus. Ass in cluster 1 0.019 (0.120) 
Coll. with Indus. Ass in cluster 2 0.558* (0.275) 
Coll. with Indus. Ass in cluster 3 -0.050 (0.119) 
Coll. with Universities in cluster 1 -0.373* (0.168) 
Coll. with Universities in cluster 2 0.052 (0.134) 
Coll. with Universities in cluster 3 -0.013 (0.104) 
Coll. with Private labs in cluster 1 -0.248 (0.175) 
Coll. with Private labs in cluster 2 -0.386* (0.185) 
Coll. with Private labs in cluster 3 -0.046 (0.086) 
Local collaboration in cluster 1 -0.256* (0.102) 
Local collaboration in cluster 2 -0.317† (0.189) 
Local collaboration in cluster 3 -0.041 (0.072) 
Intercept 0.156** (0.031) 
 
Standard deviation of the error term 
 0.186** (0.023) 
   
N                                                                                                                    103 
Log-likelihood                                                                                                -28.598 
X²(21)                                                                                                             36.813 
Significance levels: † : 10%   * : 5%  ** : 1% 
Source: WHO-INTECH survey conducted by author 
 
The econometric results show that collaboration with PRIs is positive and significant at 
5% for group 1 firms, whereas collaboration with universities is negatively significant at 
5%. Most firms admitted to having useful collaborations with PRIs as opposed to 
universities, although several firms that were interviewed admitted to having no local 
collaborations at all even with the public research institutes, due to the difficulties they 
face in speedy and efficient performance. Matrix Laboratories, for example, commended 
the facilities at the Indian Institute for Chemical Technologies (IICT) for sample analysis, 
but expressed the problems in working with them given the laxity of service and lack ofa 
market-oriented approach. Since IICT takes a week to analyze samples, firms like Matrix 
Labs feel that such long delays reduce their competitiveness (interviews). 
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This sentiment echoed through most interviews, where firms expressed their desire to 
interact better with PRIs due to their high level of infrastructure and research personnel, 
but admitted the difficulties in doing so because PRIs lacked the incentives for speedy 
performance. Factors that hinder effective collaborations with public sector institutions 
include a lack of incentives amongst researchers to engage in collaborative research with 
the private sector and bureaucratic rigidities constrain the exploration of newer ideas 
and techniques in public sector institutions, especially universities. These are 
exacerbated by micro-level factors such as intellectual isolation of researchers and lack of 
incentives for collaborative research at the individual level, such as low salaries, 
bureaucratic hassles that restrict career opportunities, inadequate research budgets, and 
lack of on-job training possibilities. Furthermore, the survey also showed that most 
collaboration between firms and PRIs was in the area of research, as opposed to product 
development, possibly for the same reason. The survey showed that 55% of firms in 
group 1 have a local collaborator focusing 42% in research activities and 22.6% in 
product development. And 23% of firms in this group have a R&D contract with 
institutions or individuals outside India. In group 2, 42% of firms in group 2 have a local 
collaborator focusing 23% in research and 23% in product development. And, 37% of 
firms in group 3 have a local collaborator focusing 26% of their efforts in research and 
10% on product development. 
 
Universities fare much worse than PRIs due to a dearth of high quality R&D in 
university departments, partly due to bureaucratic and financial constraints (CII, 1999, p. 
20) apart from the fact that several courses offered may need a higher industry 
orientation (field interviews).21 But recently, a serious effort is being made to create 
linkages between university and public research institutes and the private sector 
(Sotarauta and Srinivas, 2005). The econometric results also show that on the whole, the 
local collaborations in group 1 were negative and significant at 5%, whereas local 
collaborations for group 2 are negative and significant at 10%. 
                                                 
21  Research institutes fare much better than universities on the question of finances and human 
capital for conducting pharmaceutical research. Several of these public research institutes 
are also very active partners in international public-private partnerships, such as the Malaria 
Alliance with Ranbaxy. 
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Both formal and informal institutions affect the tendency to collaborate within systems. 
Formal institutions include rules that govern incentives for the production of skilled 
manpower, scientific infrastructure, venture capital provision and intellectual property, 
among others. Informal institutions are the customs and practices (unwritten codes of 
conduct) that govern both research-based and societal interactions. These social 
processes influence the way both formal institutions and organizations function and 
deliver results in far-reaching ways. 
 
The analysis sought to establish how different mediating variables affect both local and 
foreign collaborations. A probit model was estimated, for which the intensity of 
collaboration was taken to be 1 if collaboration with the corresponding agent was 
weighted by the firm as 3, 4 or 5 by firms (fairly strong, strong or very strong); and zero 
otherwise. Foreign R&D was taken to be 1 if the firm admitted to having overseas 
collaboration and zero otherwise. Local R&D was defined similarly. The results of the 
econometric regression are presented in Table 7. The explanatory variables in the below 
presented table are jointly significant at 0.1% level of confidence with Wald chi-square 
(12) = 39.78 and p-value = 0.0001. 
 
Table 7: Probit Estimates: the effects on local collaboration 
Variable Coefficient Std. Error 
Government innovation incentive -0.237 -0.365 
Skilled manpower -1.311* 0.632 
R&D collaboration with universities 0.093 0.385 
R&D collaboration with institutes 0.073 0.376 
IP protection    1.192*** 0.422 
Quality of infrastructure -0.973* 0.448 
Venture capital availability -0.798* 0.359 
Local SMI participation -0.819* 0.398 
Government-firm technological transfer 0.897* 0.381 
Transfers of personnel 0.447 0.378 
Small firms in 2004 -0.943* 0.399 
Medium firms in 2004 -0.496 0.359 
Intercept 1.624* 0.731 
N 102   
Log-likelihood -49.846   
chi-square (12) 39.783   
Significance levels: *10%, ** 5% and *** 1%     
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Source: WHO-INTECH survey conducted by author 
 
The results of the model suggest the following. Skilled manpower, quality of 
infrastructure and venture capital availability are all negative and significantly (10%) 
associated with the probability of establishing local collaboration. All these three factors 
are critical in the build up towards innovative activities of firms in the sector, and in the 
absence of all the three factors, firms do not have an incentive to collaborate. This is also 
clearly supported by some other results of the model. The model shows that small and 
medium firms collaborate significantly less than larger counterparts. In Table 7, local 
SMI participation is negative and significantly (10%) associated with the probability of 
establishing local collaboration. Being a small firm in 2004 is negatively and significantly 
(10%) associated with the probability of establishing local collaboration. 
 
The results show that intellectual property protection is positive and significantly (1%) 
associated with the probability of establishing local collaboration. All three groups of 
firms have tended to regard the others as rivals historically, owing to the fact that they 
competed for a share of the Indian market based on brand name rivalry. All products 
being manufactured were generics, and brand competition determined market shares 
before India’s TRIPS compliance. Intellectual property protection, clearly associated with 
innovative R&D in groups 1 and 2, is a factor prompting their strategic realignment 
towards each other to form collaborative ventures. Government-firm technological 
transfer is positive and significantly (10%) associated with the probability of establishing 
local collaboration: firms tend to collaborate more when induced to do so through 
governmental technology transfer programmes. 
 
5. Conclusion 
 
The Indian pharmaceutical industry and its strengths have been conceptualized broadly 
from two perspectives: one analyses the potential of the sector to offer price-based 
competition to the global pharmaceutical industry, by producing cost-effective generic 
versions of patented drugs. The other seeks to explore how the Indian experience can be 
 36
replicated in other developing and least developed countries.22 These perspectives stress 
upon the strengths of the Indian pharmaceutical sector to compete globally and help 
provide price competition in the generics sector to the multinational firms. 
 
The analysis conducted in the paper has shown that firms in the Indian pharmaceutical 
sector vary considerably in their innovative capabilities. They fall into three groups 
which are called the innovators, the niche operators/ collaborators and the 
manufacturers. The analysis shows that these three groups have clearly different 
configurations of a large number of innovation-related factors, such as export potential, 
skilled manpower, annual sales and R&D investments, intellectual property rights as 
well as structural properties. Based on these differences, the clusters can be interpreted 
as specific “innovation modes”, each mode being a step closer towards the innovative 
pharmaceutical firm. These differences also account for the varied challenges faced by 
each group after India’s TRIPS compliance, the main strategies and their triggers. The 
emerging firm strategies, especially those of firms in groups 1 and 2 are geared towards 
achieving higher innovation capabilities, but rely extensively on systemic factors, such 
as skilled manpower, venture capital, intellectual property institutions and increased 
collaboration. The paper has used empirical data of firms in the sector to show that the 
lack of coherence in policy processes aimed at the sector, especially in the two important 
policy phases after 1980 have not created the right incentives for systemic innovation. 
Although these policy changes contained some very essential policy aspects required for 
the sector’s growth and performance, there is a lack of a cohesive innovation policy for 
the pharmaceutical sector in India. The success stories of Group 1 firms that have 
managed to work well have come to be, because they have been able to capitalize and 
build further on the positive policy changes of the past four decades, reinforced by the 
market-based environment created by India’s liberalization. This sea-change in policy 
was reiterated consistently in several interviews with group 1 and 2 firms. In response to 
what they would like the government to do to support innovation, most firms replied 
that it would be better that the government does not intervene in any way. To a large 
extent, the activities of the bigger firms in group 1 have largely been the result not of 
                                                 
22   This is especially important now, given the new resolution that the WHO has taken on 
building capabilities. 
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cohesive innovation policy support, but of organizational incentives to compete, succeed 
and survive. 
 
Several implications for policy reform flow from the analysis. Consistent with what is 
know about sectoral systems behavior everywhere, innovation processes of Indian firms 
are strongly shaped by their specific knowledge base, qualifications and skills, required 
organizations and institutions involved, as well as specific competitive challenges from a 
globalizing economy. But the vast differences amongst firms in the sector make the case 
for differentiated policy intervention in order to harness the potential of the sector as a 
whole, and not rest our laurels on a few success stories. The analysis conducted using 
empirical data in section 4 reveals the problems in the innovation system that will affect 
the ability of firms to transform and compete in the coming years. It shows that whereas 
some aspects of innovation policy work, many other critical ones do not. Particularly, a 
small firm has several intrinsic disadvantages. Small firms belonging to group 3 are 
either static firms (unable to cope with changes to their environment) or surviving firms 
(one which can adapt and question), using the classification of this paper. The analysis 
raises a very crucial question from a policy perspective: what could be the implications 
of technological lock-in into a low equilibrium market by group 3? Several group 3 firms 
work on very small budgets and are supported through governmental schemes that 
promote small and medium enterprises. Yet, in the absence of policy foresight, these can 
be the very policies that adversely affect their movement to group 2. Hence, policies that 
help their systemic integration, enhance their ability to collaborate with other innovative 
counterparts and also learn to move up the industry value chain are urgently needed. 
The thrust of such policies will necessarily be different from those required to support 
group 1 and 2 firms.  
 
Group 1 and 2 firms, in order to capitalize on emerging market niches and to compete 
globally require policies that promote systemic innovation and enhance collaboration. 
This includes the entire range of institutions, from intellectual property to venture 
capital to skilled manpower provision. India’s potential to offer a wide range of services 
in the pharmaceutical sector competitively will depend on its systemic efficiency. Group 
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2 firms venturing out into biogenerics need a higher level of skill set to run extensive 
recombinant biological manufacturing facilities (Kamath, 2005). Until recently, not even 
ten of the top 20 biopharmaceutical companies could manufacture recombinant 
biopharmaceutials locally (ibid.).  India’s emergence as a clinical research hub or a drug 
discovery player can also be halted by a similar list of factors: lack of proper regulatory 
environment (to offer data management facilities), lack of skilled labour and lack of 
organizational skills. Differentiated policy that targets at empowering each firm group 
to the best possible extent will help harness the potential of the sector as a whole. 
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